DIA会员及用户请点击登录

登录

忘记用户 ID? or 忘记密码?

Not a Member?

创建账户并加入。

Hilton Mexico City Reforma

2026 年 09 月 09 日 1:00 下午 - 2026 年 09 月 11 日 2:45 下午

Avenida Juárez #70, Col. Centro Delegación Cuauhtémoc, Ciudad de México, 06010 Mexico

Latin America Annual Meeting

Take advantage of opportunities for networking and knowledge sharing with key stakeholders influencing the advancement and implementation of initiatives in Latin America and the Caribbean.

Early Bird Ends

DAYS

HOURS

MINUTES

SECONDS

Session 7, Track B: Responsible AI for Safer Medicines - Advancing Pharmacovigilance Quality and Decision Making in Latin America

Session Chair(s)

Juan  Asbun

Juan Asbun

Pharmacovigilance and Patient Safety Regional Lead, Takeda México, S.A. De C.V., Mexico

Diana  Gonzalez, MD, MBA

Diana Gonzalez, MD, MBA

Colombia PSL & PV Policy Lead Latam , Roche, Colombia

Artificial intelligence (AI) is rapidly transforming pharmacovigilance, redefining how drug risks are identified, analyzed, and communicated throughout their lifecycle. This symposium examines the emerging role of AI in risk management and safety communication, highlighting how these technologies can enhance—and not replace—scientific and regulatory judgment. The session will address the application of AI and machine learning models in key areas such as early detection of signals,risk prioritization, automation of pharmacovigilance processes, and evaluation of the effectiveness of risk minimization measures. Moreover, the discourse will address the bioethical and quality considerations inherent in the deployment of AI within pharmacovigilance.

Learning Objective :
  • Describe concrete applications of AI in pharmacovigilance risk management
  • Identify the requirements for the responsible implementation of AI in pharmacovigilance and relate them to current regulatory expectations.
  • Define a specific and feasible action to incorporate or evaluate the use of AI in a risk management or communication process across pharmacovigilance processes

获得信息并保持参与

不要错失任何机会——请加入我们的邮件列表,了解DIA的观点和事件。